Post-activity questions

Please complete the following questions. Those marked with an asterick(*) are required.

Question Title

* Which antiemetic regimen is recommended by all major international guidelines for acute emesis in a patient receiving carboplatin (AUC 6)?

5-HT3 RA + dexamethasone

NK1 RA + 5-HT3 RA + dexamethasone

NK1 RA + 5-HT3 RA + dexamethasone + olanzapine

5-HT3 RA + dexamethasone + olanzapine

Question Title

* Which of the following is not true regarding NK1 RAs?

All selectively block the binding of substance P at the NK1 receptor

Oral formulations provide comparable efficacy and safety profiles

Similar half-life profiles for aprepitant, netupitant and rolapitant allow for single-day dosing regimens

Offer convenience in the form of a fixed-dose combination with 5-HT3 RA (e.g. NEPA)

Question Title

* Based on the CINV risk prediction model to assess individualized risk for grade ≥ 2 CINV (Dranitsaris Ann Oncol 2017), which variable is not predictive of CINV?

Age < 60 years

History of alcohol consumption

Hours of sleep the night prior to chemotherapy

CINV in the previous cycle

Question Title

* How often do you now PLAN TO DO the following:

	Never	Rarely	Sometimes	Most of the time	Always	NA
Apply current guidelines to select antiemetic prophylaxis for patients receiving HEC, MEC regimens	Apply current guidelines to select antiemetic prophylaxis for patients receiving HEC, MEC regimens Never	Apply current guidelines to select antiemetic prophylaxis for patients receiving HEC, MEC regimens Rarely	Apply current guidelines to select antiemetic prophylaxis for patients receiving HEC, MEC regimens Sometimes	Apply current guidelines to select antiemetic prophylaxis for patients receiving HEC, MEC regimens Most of the time	Apply current guidelines to select antiemetic prophylaxis for patients receiving HEC, MEC regimens Always	Apply current guidelines to select antiemetic prophylaxis for patients receiving HEC, MEC regimens NA
Consider fixed-combination strategies to simplify antiemetic treatment regimens	Consider fixed-combination strategies to simplify antiemetic treatment regimens Never	Consider fixed-combination strategies to simplify antiemetic treatment regimens Rarely	Consider fixed-combination strategies to simplify antiemetic treatment regimens Sometimes	Consider fixed-combination strategies to simplify antiemetic treatment regimens Most of the time	Consider fixed-combination strategies to simplify antiemetic treatment regimens Always	Consider fixed-combination strategies to simplify antiemetic treatment regimens NA
Use an NK1 receptor antagonist of fixed-combination regimen in patients receiving carboplatin-based chemotherapy	Use an NK1 receptor antagonist of fixed-combination regimen in patients receiving carboplatin-based chemotherapy Never	Use an NK1 receptor antagonist of fixed-combination regimen in patients receiving carboplatin-based chemotherapy Rarely	Use an NK1 receptor antagonist of fixed-combination regimen in patients receiving carboplatin-based chemotherapy Sometimes	Use an NK1 receptor antagonist of fixed-combination regimen in patients receiving carboplatin-based chemotherapy Most of the time	Use an NK1 receptor antagonist of fixed-combination regimen in patients receiving carboplatin-based chemotherapy Always	Use an NK1 receptor antagonist of fixed-combination regimen in patients receiving carboplatin-based chemotherapy NA

Thank you for your time and participation.

Please click the SUBMIT button below to complete this activity.